Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

British Medical JournalNirmatrelvir and Risk of Hospital Admission or Death in Adults with COVID-19: Emulation of a Randomized Target Trial Using Electronic Health Records

In a study of 256,288 individuals who tested positive for COVID-19 and had at least one risk factor for developing severe COVID, regardless of immunization, booster, or prior infection history, treatment with nirmatrelvir reduced rates of hospital admission or death at 30 days.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Epoch Health
Healthgrades for Professionals
MDLinx
Neurology Advisor
Oncology Learning Network
Oncology News Central (ONC)
Psych Congress Network
Psychiatrist.com
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form